Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEMOTRAD 01
2018-002654-79Phase 2Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temozolomide in brainstem glioma and malignant glioma, sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Clinical and radiological response rate. Started Sep 2018; status: active.
02
Drugs
temozolomide
03
Conditions
brainstem gliomamalignant glioma
Beyond the preview
Go deeper on 2018-002654-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002654-79.